Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review
Renal transplant recipients treated with calcineurin inhibitors (CNIs) are at a high risk of developing a skin cancer. Therefore, new therapeutic options such as inhibitors of the mammalian target of rapamycin (mTORi) have been studied to find treatment regimens decreasing the rate of skin cancers....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2023-06-01
|
| Series: | Advances in Dermatology and Allergology |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Non-melanoma-skin-cancer-outcomes-in-kidney-r-ntransplant-recipients-converted-from-calcineurin-r-ninhibitors-to-mTOR-inhibitors-a-systematic-review,7,50711,1,1.html |
| _version_ | 1797692324555259904 |
|---|---|
| author | Berenika Olszewska Beata Imko-Walczuk Alicja Dębska-Ślizień |
| author_facet | Berenika Olszewska Beata Imko-Walczuk Alicja Dębska-Ślizień |
| author_sort | Berenika Olszewska |
| collection | DOAJ |
| description | Renal transplant recipients treated with calcineurin inhibitors (CNIs) are at a high risk of developing a skin cancer. Therefore, new therapeutic options such as inhibitors of the mammalian target of rapamycin (mTORi) have been studied to find treatment regimens decreasing the rate of skin cancers. This systematic review focuses on recent randomized controlled trials studying the impact of conversion from CNI to mTORi in renal transplant recipients on development of non-melanoma skin cancers (NMSC). Outcomes of analysed trials revealed that conversion from CNI to mTORi in post-transplant patients reduces the risk and delays the occurrence of NMSC. However, mTORi protective properties against NMSC are more effective in patients with a history of a single SCC compared with multiple SCCs. At the same time, conversion to mTORi is associated with more common discontinuations secondary to adverse events and also increased mortality. In conclusion, conversion to mTORi is protective against NMSC but given the high AE rates and therapy discontinuation there is a need to determine who would benefit from conversion and search for new treatment regimens including combination strategies with mTORi. |
| first_indexed | 2024-03-12T02:26:59Z |
| format | Article |
| id | doaj.art-63f352dadaa848a082d463d592114d09 |
| institution | Directory Open Access Journal |
| issn | 1642-395X 2299-0046 |
| language | English |
| last_indexed | 2024-03-12T02:26:59Z |
| publishDate | 2023-06-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Advances in Dermatology and Allergology |
| spelling | doaj.art-63f352dadaa848a082d463d592114d092023-09-05T11:51:56ZengTermedia Publishing HouseAdvances in Dermatology and Allergology1642-395X2299-00462023-06-0140218719310.5114/ada.2023.12763750711Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic reviewBerenika OlszewskaBeata Imko-WalczukAlicja Dębska-ŚlizieńRenal transplant recipients treated with calcineurin inhibitors (CNIs) are at a high risk of developing a skin cancer. Therefore, new therapeutic options such as inhibitors of the mammalian target of rapamycin (mTORi) have been studied to find treatment regimens decreasing the rate of skin cancers. This systematic review focuses on recent randomized controlled trials studying the impact of conversion from CNI to mTORi in renal transplant recipients on development of non-melanoma skin cancers (NMSC). Outcomes of analysed trials revealed that conversion from CNI to mTORi in post-transplant patients reduces the risk and delays the occurrence of NMSC. However, mTORi protective properties against NMSC are more effective in patients with a history of a single SCC compared with multiple SCCs. At the same time, conversion to mTORi is associated with more common discontinuations secondary to adverse events and also increased mortality. In conclusion, conversion to mTORi is protective against NMSC but given the high AE rates and therapy discontinuation there is a need to determine who would benefit from conversion and search for new treatment regimens including combination strategies with mTORi.https://www.termedia.pl/Non-melanoma-skin-cancer-outcomes-in-kidney-r-ntransplant-recipients-converted-from-calcineurin-r-ninhibitors-to-mTOR-inhibitors-a-systematic-review,7,50711,1,1.htmlcalcineurin inhibitor mtor inhibitor skin cancer transplantation |
| spellingShingle | Berenika Olszewska Beata Imko-Walczuk Alicja Dębska-Ślizień Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review Advances in Dermatology and Allergology calcineurin inhibitor mtor inhibitor skin cancer transplantation |
| title | Non-melanoma skin cancer outcomes in kidney
transplant recipients converted from calcineurin
inhibitors to mTOR inhibitors: a systematic review |
| title_full | Non-melanoma skin cancer outcomes in kidney
transplant recipients converted from calcineurin
inhibitors to mTOR inhibitors: a systematic review |
| title_fullStr | Non-melanoma skin cancer outcomes in kidney
transplant recipients converted from calcineurin
inhibitors to mTOR inhibitors: a systematic review |
| title_full_unstemmed | Non-melanoma skin cancer outcomes in kidney
transplant recipients converted from calcineurin
inhibitors to mTOR inhibitors: a systematic review |
| title_short | Non-melanoma skin cancer outcomes in kidney
transplant recipients converted from calcineurin
inhibitors to mTOR inhibitors: a systematic review |
| title_sort | non melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mtor inhibitors a systematic review |
| topic | calcineurin inhibitor mtor inhibitor skin cancer transplantation |
| url | https://www.termedia.pl/Non-melanoma-skin-cancer-outcomes-in-kidney-r-ntransplant-recipients-converted-from-calcineurin-r-ninhibitors-to-mTOR-inhibitors-a-systematic-review,7,50711,1,1.html |
| work_keys_str_mv | AT berenikaolszewska nonmelanomaskincanceroutcomesinkidneytransplantrecipientsconvertedfromcalcineurininhibitorstomtorinhibitorsasystematicreview AT beataimkowalczuk nonmelanomaskincanceroutcomesinkidneytransplantrecipientsconvertedfromcalcineurininhibitorstomtorinhibitorsasystematicreview AT alicjadebskaslizien nonmelanomaskincanceroutcomesinkidneytransplantrecipientsconvertedfromcalcineurininhibitorstomtorinhibitorsasystematicreview |